Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.

image

Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma. – Nanotechnology News Today – EIN Presswire

Trusted News Since 1995

A service for nanotechnology industry professionals
·
Tuesday, January 24, 2023

·
613,065,610
Articles


·
3+ Million Readers

News Monitoring and Press Release Distribution Tools

News Topics

Newsletters

Press Releases

Events & Conferences

RSS Feeds

Other Services

Questions?

Peyman Taeidi

Leave a Reply

Your email address will not be published. Required fields are marked *